---
document_datetime: 2023-09-21 17:36:04
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/steps-after-cutoff/procomvax-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
document_name: procomvax-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
version: success
processing_time: 1.2302624
conversion_datetime: 2025-12-23 04:01:54.968063
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## STEPS TAKEN AFTER GRANTING THE MARKETING AUTHORISATION

For procedures finalised after 01/09/2004, please refer to module 8B

<!-- image -->

Medicinal product no longer authorised · The  MAH  submitted  in  accordance  with  Commission  Regulation  (EC)  No.  542/95  an application for a Type II variation relating to the extension of the storage time of the yeast cell paste intermediate product of the hepatitis B component of Procomvax, from 12 to 24 months. The  EMEA  adopted  a  positive  opinion  on  29  July  1999.  Type  II  -  Quality:  Update  of  or change(s) to the pharmaceutical documentation · The  MAH  submitted  in  accordance  with  Commission  Regulation  (EC)  No.  542/95  an application  for  a  Type  II  variation  relating  to  the  scale  up  of  the  hepatitis  B  component  of Procomvax  in  a  new  fermentation  facility.  The  EMEA  adopted  a  positive  opinion  on 29 July 1999. Type II - Quality: Update of or change(s) to the pharmaceutical documentation · The  MAH  submitted  in  accordance  with  Commission  Regulation  (EC)  No.  542/95  an application for a Type I variation relating to an extension of shelf-life of the finished product from 24 months to 36 months, at 2 - 8 °C. The EMEA notified the European Commission and the MAH on 14 July 1999 that the variation is accepted. The Commission Decision amending the Community Marketing Authorisation was adopted on 30 September 1999. Quality change: Extension of shelf life as foreseen at time of authorisation. · The  MAH  submitted  in  accordance  with  Commission  Regulation  (EC)  No.  542/95  an application  for  a  Type  II  variation  relating  to  the  addition  of  plastic  bags  as  an  alternative storage  container  for  Hepatitis B  yeast  cell  paste.  The  EMEA  adopted  a  positive  opinion  on 19 January 2000. Quality change: Change to the pharmaceutical documentation · The  MAH  submitted  in  accordance  with  Commission  Regulation  (EC)  No.  542/95  an application for a Type I variation relating to an extension of shelf-life of the active substance (Haemophilus  b  Bulk)  from  24  months  to  36  months,  at  2  -  8  °C  The  EMEA  notified  the European Commission and the MAH on 19 April 2000 that the variation is accepted. Quality change: Extension of the shelf life or retest period of the active substance. · The  MAH submitted in  accordance  with  Article  10(3)  of  Council  Directive  No.  92/27/EE,  a notification  of  a  change  of  the  local  representatives  for  Greece  and  Germany  in  the  Package Leaflet text (Annex  IIIB) in all  language  versions  The  EMEA  notified  the  European Commission and the MAH on 31 January 2000 that the change is accepted. The Commission Decision amending the Community Marketing Authorisation was adopted on 20 March 2000. · The  MAH  submitted  in  accordance  with  Commission  Regulation  (EC)  No.  542/95  an application for a Type I variation relating to a change in the name of the marketing authorisation holder from Pasteur Mérieux MSD S.N.C. to Aventis Pasteur MSD S.N.C. The EMEA notified the European Commission and the MAH on 16 May 2000 that the variation is accepted. The Commission  Decision  amending  the  Community  Marketing  Authorisation  was  adopted  on 11 July 2000.

<div style=\"page-break-after: always\"></div>

Subsequent post Marketing Authorisation applications agreed upon are summarised in the table below:

| Scope                                                                                                                                                                                    | Applicatio n number   | Type of modificati on 1   | Notificatio n/ Opinion issued on 2   | Commissi on Decision Issued/am ended on   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|---------------------------|--------------------------------------|-------------------------------------------|
| Quality changes: Update of or change(s) to the pharmaceutical documentation                                                                                                              | II/0007               | II                        | 19.10.00                             | 14.11.00                                  |
| Quality changes: Change(s) to the test method(s) and/or specifications for the active substance. Quality: Change(s) to the test method(s) and/or specifications for the finished product | II/0009               | II                        | 19.10.00                             | 14.11.00                                  |
| Quality changes: Change(s) to the manufacturing process for the active substance                                                                                                         | II/0010               | II                        | 31.05.01                             | 21.06.01                                  |
| Quality changes: Update of or change(s) to the pharmaceutical documentation                                                                                                              | II/0011               | II                        | 23.08.01                             | 07.09.01                                  |
| Changes to the Patient Leaflet regarding some MAH local representative details                                                                                                           | N/0012                | N                         | 13.07.01                             | 13.08.01                                  |
| Changes to the Patient Leaflet regarding the transfer of some MAHlocal representatives                                                                                                   | N/0013                | longer N                  | 13.09.02                             | 10.10.02                                  |
| Quality changes: Change(s) to shelf-life or storage conditions.                                                                                                                          | II/14                 | II                        | 25.09.03                             | 02.10.03                                  |
| Renewal of the Marketing Authorisation.                                                                                                                                                  | R/0015                | R                         | 24.03.04                             | 02.08.04                                  |
| Quality changes: Change(s) to the test method(s) and/or specifications for the active substance                                                                                          | II/0016               | II                        | 29.07.04                             | 02.08.04                                  |

1 In accordance with Commission Regulation (EC) No. 542/95 of 10 Mar 1995, as amended: I refers to a minor variation (Type I variation); II refers to a major variation (Type II variation); I/II refers to a minor variation following the procedure set out in Article 6, 7 and 8 of the Regulation; X refers to an Annex II application. T refers to a transfer of a Marketing Authorisation in accordance with Commission Regulation (EC) No 2141/96 of 7 November 1996.

<!-- image -->